Cefepime/zidebactam
| Combination of | |
|---|---|
| Cefepime | Cephalosporin antibacterial |
| Zidebactam | Beta-lactamase inhibitor and non-beta-lactam antibacterial |
| Clinical data | |
| Trade names | Zaynich |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Cefepime/zidebactam, sold under the brand name Zaynich, is a fixed-dose combination used for the treatment of complicated urinary tract infections.[1] It contains cefepime, a cephalosporin antibacterial; and zidebactam, a beta-lactamase inhibitor and non-beta-lactam antibacterial.[1]
It was approved for medical use in the United States in May 2026.[2]
Medical uses
Cefepime/zidebactam is indicated for the treatment of adults with complicated urinary tract infections including pyelonephritis caused by designated susceptible microorganisms.[1]
Society and culture
Legal status
Cefepime/zidebactam was approved for medical use in the United States in May 2026.[2][3]
Names
Cefepime/zidebactam is sold under the brand name Zaynich.[2]
References
- 1 2 3 4 "Prescription label" (PDF). Accessdate.fda.gov. Retrieved 15 July 2026.
- 1 2 3 "Novel Drug Approvals for 2026". U.S. Food and Drug Administration (FDA). 1 June 2026. Retrieved 5 June 2026.
- ↑ "Wockhardt Receives U.S. FDA Approval for Zaynich (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis" (Press release). Wockhardt. 1 June 2026. Retrieved 5 June 2026 – via PR Newswire.